Docoh
Loading...

LIXT Lixte Biotechnology

Filed: 13 Oct 21, 10:01am

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 8, 2021

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

delaware 001-39717 20-2903526

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

680 East Colorado Boulevard, Suite 180

Pasadena, California 91101 

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol(s) Name of each exchange on which registered
Common Stock LIXT The Nasdaq Stock Market LLC
Warrant to Purchase Common Stock LIXTW The Nasdaq Stock Market LLC

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Development and Collaboration Agreement

 

On October 8, 2021, Lixte Biotechnology Holdings, Inc. (the “Company”) entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam (NKI), one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.

 

Item 8.01 Other Events.

 

On October 13, 2021, the Company issued a press release with respect to its entry into the Development Collaboration Agreement.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The Company is filing as part of this report the exhibits listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.

 

 -2- 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 LIXTE BIOTECHNOLOGY HOLDINGS, INC.
   
Date: October 13, 2021By:/s/ JOHN S. KOVACH
  John S. Kovach, President and Chief Executive Officer

 

 -3- 

 

 

INDEX TO EXHIBITS

 

Exhibit No. Description
   
99.1 

Press Release Announcing Entry into Development Collaboration Agreement

   
104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 -4-